U.S. Markets close in 14 mins

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
25.81-0.02 (-0.08%)
As of 03:46PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.83
Bid25.92 x 800
Ask25.97 x 1300
Day's Range25.19 - 26.73
52 Week Range10.86 - 36.42
Avg. Volume2,243,303
Market Cap1.057B
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-0.81
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.88
  • Benzinga

    Xenon Pharmaceuticals Insider Sold Over $550K In Company Stock

    Simon Pimstone, Insider at Xenon Pharmaceuticals (NASDAQ:XENE), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Pimstone sold 17,557 shares of Xenon Pharmaceuticals at a price of $31.33. The total transaction amounted to $550,061. Pimstone still owns a total of 210,186 shares of Xenon Pharmaceuticals worth, $6,568,312. Xenon Pharmaceuticals shares are trading down 2.31%

  • GlobeNewswire

    Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

    BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will participate virtually in the following investor conferences: Guggenheim 3rd Annual Neuro/Immunology Conference on Monday, November 15, 2021 (one-on-one meetings only)Stifel 2021 Virtual Healthcare Conferen

  • Zacks

    Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue Estimates

    Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 18.18% and 4.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?